These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16235180)

  • 1. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine.
    Miiro G; Kayhty H; Watera C; Tolmie H; Whitworth JA; Gilks CF; French N
    J Infect Dis; 2005 Nov; 192(10):1801-5. PubMed ID: 16235180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.
    Lesprit P; Pédrono G; Molina JM; Goujard C; Girard PM; Sarrazin N; Katlama C; Yéni P; Morineau P; Delfraissy JF; Chêne G; Lévy Y;
    AIDS; 2007 Nov; 21(18):2425-34. PubMed ID: 18025879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults.
    French N; Moore M; Haikala R; Kayhty H; Gilks CF
    J Infect Dis; 2004 Aug; 190(4):707-12. PubMed ID: 15272398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-sectional study of nasopharyngeal carriage of Streptococcus pneumoniae in human immunodeficiency virus-infected adults in the conjugate vaccine era.
    Onwubiko C; Swiatlo E; McDaniel LS
    J Clin Microbiol; 2008 Nov; 46(11):3621-5. PubMed ID: 18845823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults.
    Peñaranda M; Payeras A; Cambra A; Mila J; Riera M;
    AIDS; 2010 May; 24(8):1226-8. PubMed ID: 20299956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
    Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
    Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults.
    Chen M; Ssali F; Mulungi M; Awio P; Yoshimine H; Kuroki R; Furumoto A; Tanimura S; Kityo C; Nagatake T; Mugyenyi P; Oishi K
    Vaccine; 2008 Sep; 26(38):4962-8. PubMed ID: 18639599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
    Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
    Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
    Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
    Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine.
    Long SS
    Clin Infect Dis; 2005 Jul; 41(1):30-4. PubMed ID: 15937759
    [No Abstract]   [Full Text] [Related]  

  • 16. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
    Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
    HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.
    Søgaard OS; Lohse N; Harboe ZB; Offersen R; Bukh AR; Davis HL; Schønheyder HC; Østergaard L
    Clin Infect Dis; 2010 Jul; 51(1):42-50. PubMed ID: 20504165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years.
    Goldblatt D; Southern J; Andrews N; Ashton L; Burbidge P; Woodgate S; Pebody R; Miller E
    Clin Infect Dis; 2009 Nov; 49(9):1318-25. PubMed ID: 19814624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.
    Siber GR; Chang I; Baker S; Fernsten P; O'Brien KL; Santosham M; Klugman KP; Madhi SA; Paradiso P; Kohberger R
    Vaccine; 2007 May; 25(19):3816-26. PubMed ID: 17368878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.
    Madhi SA; Adrian P; Kuwanda L; Jassat W; Jones S; Little T; Soininen A; Cutland C; Klugman KP
    Vaccine; 2007 Mar; 25(13):2451-7. PubMed ID: 17023095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.